A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) SAN FRANCISCO, June 2, 2026 /PRNewswire/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc....
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP) SAN FRANCISCO, June 2, 2026 /PRNewswire/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc....
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.